Stocks Health care BCAX
NASDAQ · Health careBicara Therapeutics Inc. (BCAX)
It posted a net loss of $220.3M. In fiscal 2025 capital spending exceeded operating cash flow by $107.1M. At September 30, 2026 it held $82M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Bicara Therapeutics Inc.
- Net worth
- Bicara Therapeutics Inc. has a market value (market cap) of $651.1M at the latest share price, and shareholders' equity of $409.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $106.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Bicara Therapeutics Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Bicara Therapeutics Inc. does
Bicara Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BCAX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$138M | -$2.52 | -$107.1M |
| 2024 | n/a | -$68M | -$4.05 | -$74.8M |
| 2024 | n/a | -$52M | -$89.61 | -$46.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Bicara Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- August 25, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 11, 2026
- July 28, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Bicara Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $400.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 8, 2026 | Cohlhepp RyanPresident, COO & Interim CEO, Director | Exercised options | 17,500 | $66.3K |
| September 8, 2026 | Cohlhepp RyanPresident, COO & Interim CEO, Director | Soldpre-planned (10b5-1) | 14,058 | $320.1K |
| September 8, 2026 | Cohlhepp RyanPresident, COO & Interim CEO, Director | Soldpre-planned (10b5-1) | 3,442 | $80.7K |
| August 10, 2026 | Cohlhepp RyanPresident and COO, Director | Exercised options | 18,750 | $71.1K |
| August 10, 2026 | Cohlhepp RyanPresident and COO, Director | Soldpre-planned (10b5-1) | 18,750 | $524.5K |
| August 10, 2026 | Mazumdar ClaireChief Executive Officer, Director | Exercised options | 10,000 | $37.9K |
| August 10, 2026 | Mazumdar ClaireChief Executive Officer, Director | Soldpre-planned (10b5-1) | 10,000 | $279.8K |
| August 10, 2026 | Hyep IvanChief Financial Officer | Exercised options | 12,500 | $47.4K |
Who owns BCAX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 11.5% | March 2, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 10.1% | April 8, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 9.6% | July 31, 2025 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 8.3% | May 15, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 6.21% | May 15, 2026 |
| Tpg GP A, LLC13D, may seek influence with 3 related filers | 5.5% | September 18, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 171 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 7,255,993 | 0 |
| Siren, L.L.C. | 5,602,970 | -200,000 |
| Vestal Point Capital, LP | 5,250,000 | -175,000 |
| Deep Track Capital, LP | 4,100,000 | +37,500 |
| BlackRock, Inc. | 3,848,090 | +1,004,383 |
| Jupiter Topco LLC | 3,171,015 | new |
| Red Tree Management, LLC | 3,163,517 | -6,992 |
| Tpg GP A, LLC | 3,010,425 | 0 |
| Vanguard Capital Management LLC | 2,216,639 | +442,419 |
| State Street Corp | 2,048,920 | +629,532 |
| Franklin Resources Inc | 1,951,892 | +330,249 |
| Fmr LLC | 1,893,070 | -207,859 |
| Omega Fund Management, LLC | 1,822,150 | -570,000 |
| Geode Capital Management, LLC | 1,162,635 | +331,729 |
| Jpmorgan Chase & Co | 1,015,965 | +838,557 |
| Jones Hill Capital LP | 892,621 | -367,515 |
| Acorn Capital Advisors, LLC | 643,381 | -1 |
| Aisling Capital Management LP | 568,919 | 0 |
| Palo Alto Investors LP | 550,408 | 0 |
| Rock Springs Capital Management LP | 535,286 | +46,191 |
Insiders
5 insiders reported holding 5,332,352 shares in total, about $52.5M at the last price.
| Holder | Shares |
|---|---|
| Ra Capital Management, L.P.Director, 10% owner | 4,603,4184,603,418 held indirectly |
| Mazumdar ClaireChief Executive Officer, Director | 362,152 |
| Cohlhepp RyanPresident, COO & Interim CEO, Director | 181,641 |
| Hyep IvanChief Financial Officer | 129,855 |
| Raben DavidChief Medical Officer | 55,286 |
Questions about BCAX
What does Bicara Therapeutics Inc. do?
Bicara Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as BCAX. Its shares trade on NASDAQ under the ticker BCAX.
What is Bicara Therapeutics Inc.'s net worth?
Bicara Therapeutics Inc. has a market value (market cap) of $651.1M at the latest share price, and shareholders' equity of $409.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bicara Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $220.3M.
When did Bicara Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Bicara Therapeutics Inc.'s next earnings report?
Bicara Therapeutics Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BCAX with
Follow BCAX
Get an email when Bicara Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bicara Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.